Kardigan, Inc. (Nasdaq: KARD), a clinical-stage company focused on cardiovascular therapeutics, has set the initial public offering price at $16 a share for 25 million common shares, the company said in a press release.
At that price, the offering is expected to produce gross proceeds of $400 million prior to the deduction of underwriting discounts, commissions and other expenses. Kardigan has also provided the underwriters with a 30-day option to buy up to an additional 3.75 million shares at the IPO price, which would raise the total proceeds if that option is exercised. All of the shares in the offering are being sold by the company.
The company indicated that its shares were expected to begin trading on the Nasdaq Global Market on June 18, 2026. The offering was expected to close on June 20, 2026, subject to customary closing conditions.
J.P. Morgan Securities LLC, Jefferies LLC, Leerink Partners LLC and TD Securities (USA) LLC are listed as the underwriters for the transaction.
Kardigan is based in South San Francisco, California, and Princeton, New Jersey. The company describes its focus as developing treatments for cardiovascular diseases for which there are currently no approved therapies.
Context and implications
The IPO funds, if raised as expected, would represent gross proceeds before underwriting and offering expenses. The underwriters' 30-day option to purchase additional shares is a standard mechanism that can increase the size of an offering if demand warrants it. The schedule provided by the company sets a clear timeline for the listing and closing, though both milestones remain subject to customary closing conditions.
This filing positions Kardigan to access public capital markets with an offering administered by a syndicate of established investment banks. The company's dual-location footprint is noted as South San Francisco and Princeton, New Jersey, and its stated clinical focus is on cardiovascular conditions that currently lack approved therapies.